Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage Morphine is used for the management of chronic, moderate to severe pain.[A176050] Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.[L5728]
Marketing Status approved; investigational
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
UNII 76I7G6D29C
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Slow response to stimuli17.02.05.0630.000111%Not Available
Symptom masked08.01.03.0780.000557%Not Available
Systemic mastocytosis16.21.01.008; 01.13.01.008; 10.02.01.0140.000223%Not Available
Trance19.01.02.018--Not Available
Aneurysm ruptured24.02.01.0020.000111%Not Available
Terminal state08.01.03.0790.000446%Not Available
Arachnoid cyst17.18.05.001; 16.09.05.0010.000111%Not Available
Neonatal hypotension24.06.03.014; 18.04.07.0080.000167%Not Available
Live birth18.08.02.0070.000167%Not Available
Self esteem decreased19.05.02.0040.001559%Not Available
Encephalomalacia17.11.01.016--Not Available
Acute chest syndrome24.03.08.006; 22.06.03.004; 01.04.02.0040.000390%Not Available
Self esteem inflated19.05.02.0030.000111%Not Available
Bradycardia neonatal18.04.07.004; 02.03.02.0190.000167%Not Available
Palatal oedema07.05.04.0080.000223%Not Available
Biliary dilatation09.02.03.0040.000278%Not Available
Arterial stenosis24.04.02.0120.000111%Not Available
Communication disorder19.19.01.0080.000278%Not Available
Foetal heart rate disorder18.03.02.014; 02.03.02.0250.000167%Not Available
Foaming at mouth07.05.05.019; 17.02.05.056; 08.01.03.070--Not Available
Spinal cord oedema17.10.01.0190.000167%Not Available
Pruritus allergic10.01.03.046; 23.03.12.0100.000568%Not Available
Accidental death08.04.01.013; 12.01.08.0400.000111%Not Available
Neurodevelopmental disorder17.02.10.031; 19.22.02.0030.000111%Not Available
Fear of death19.06.03.0060.000245%Not Available
Aortic intramural haematoma24.02.03.0040.000167%Not Available
Foetal hypokinesia18.03.02.0150.000111%Not Available
Acute lung injury22.01.03.0100.000390%Not Available
Sensitivity to weather change08.01.03.077--Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000835%Not Available
The 18th Page    First    Pre   18 19 20    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene